91591-72-9

Usage

Uses

Used in Agrochemical Industry:
2,4-DICHLORO-6-METHYLNICOTINALDEHYDE is used as an active ingredient for its strong antimicrobial and pesticidal properties, enhancing the effectiveness of agricultural products in controlling pests and diseases.
Used in Pharmaceutical Industry:
2,4-DICHLORO-6-METHYLNICOTINALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and treatments.
Used in Chemical Synthesis:
2,4-DICHLORO-6-METHYLNICOTINALDEHYDE is used as a building block in the synthesis of other organic compounds, facilitating the creation of a wide range of chemical products.
Used in Chemical Biology Research:
2,4-DICHLORO-6-METHYLNICOTINALDEHYDE serves as a research tool in chemical biology, aiding scientists in understanding the interactions between small molecules and biological systems, and in the discovery of new bioactive compounds.

Upstream product

• 374800-25-6 2,4-Dichloro-3-hydroxymethyl-6-methylpyridine 
• 86129-63-7 ethyl 2,4-dichloro-6-methylpyridine-3-carboxylate 
• 28466-26-4 4-aminopyrazole 
• 141-97-9 ethyl acetoacetate 
• 138642-40-7 methyl 2,4-dichloro-6-methylpyridine-3-carboxylate 

Downstream Products

• 1347759-40-3 4-chloro-3-iodo-6-methyl-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 1347759-41-4 3-iodo-4-methoxy-6-methyl-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 1347759-42-5 3-iodo-6-methyl-4-(tetrahydro-2H-pyran-4-yloxy)-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 1347759-43-6 4-(4-(4-methoxy-6-methyl-1-trityl-1H-pyrazolo[4,3-c]pyridin-3-yl)pyridin-2-yl)morpholine 
• 1347759-44-7 6-methyl-3-(1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 1347759-45-8 6-methyl-3-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 1347759-46-9 C₃₈H₃₆N₆O₂ 
• 1347759-48-1 C₄₀H₃₆N₆O₃ 
• 1347759-50-5 1-(4-methoxybenzyl)-6-methyl-N-(tetrahydro-2H-pyran-4-yl)-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine 
• 1347758-91-1 C₁₄H₂₀N₄ 
• 1347758-92-2 C₁₄H₁₉N₃O 
• 1347759-23-2 3-iodo-4-(tetrahydro-2H-pyran-4-yloxy)-1-trityl-1H-pyrazolo[4,3-c]pyridine-6-carbaldehyde 
• 1347759-24-3 3-iodo-4-(tetrahydro-2H-pyran-4-yloxy)-1-trityl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile 
• 1159828-70-2 4-chloro-6-methyl-1H-pyrazolo[4,3-c]pyridine 

Relevant academic research and scientific papers

TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS

The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions

PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2

A compound of formula la or formula lb, or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4-7-heterocycloalkyl; - CONR4R5; -NHCO

Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core

Two new classes of tricyclic-based corticotropin-releasing factor (CRF 1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same